These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29335712)

  • 1. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    Lønning PE; Berge EO; Bjørnslett M; Minsaas L; Chrisanthar R; Høberg-Vetti H; Dulary C; Busato F; Bjørneklett S; Eriksen C; Kopperud R; Axcrona U; Davidson B; Bjørge L; Evans G; Howell A; Salvesen HB; Janszky I; Hveem K; Romundstad PR; Vatten LJ; Tost J; Dørum A; Knappskog S
    Ann Intern Med; 2018 Mar; 168(5):326-334. PubMed ID: 29335712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
    Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
    Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
    Kontorovich T; Cohen Y; Nir U; Friedman E
    Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
    Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR
    Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
    Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
    J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
    Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential.
    Wiley A; Katsaros D; Chen H; Rigault de la Longrais IA; Beeghly A; Puopolo M; Singal R; Zhang Y; Amoako A; Zelterman D; Yu H
    Cancer; 2006 Jul; 107(2):299-308. PubMed ID: 16773633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
    Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
    Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.